• Molecular NameOrciprenaline
  • SynonymMetaproterenol; Metaproterenol Sulfate; Orciprenalina [INN-Spanish]; Orciprenaline Sulfate; Orciprenalinum [INN-Latin]
  • Weight211.261
  • Drugbank_IDDB00816
  • ACS_NO586-06-1
  • Show 2D model
  • LogP (experiment)0.2
  • LogP (predicted, AB/LogP v2.0)-0.08
  • pkapKa9.0 (—OH), 10.1 (—NH—), 11.4 (—OH), (25°)
  • LogD (pH=7, predicted)-2.77
  • Solubility (experiment)0.0097 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.1
  • LogSw (predicted, AB/LogsW2.0)142.85
  • Sw (mg/ml) (predicted, ACD/Labs)5.99
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds4
  • TPSA72.72
  • StatusFDA approved
  • AdministrationInhalation / tablets
  • PharmacologyA bronchodilator used in the treatment of asthma.
  • Absorption_value43.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability20.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmGastrointestinal and hepatic. The major metabolite, metaproterenol-3-0-sulfate, is produced in the gastrointestinal tract. Alupent is not metabolized by catechol-0-methyltransferase nor have glucuronide conjugates been isolated to date.
  • Half life6 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include angina, hypertension or hypotension, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise and insomnia.
  • LD50 (rat)LD50=42 mg/kg
  • LD50 (mouse)N/A